OBLN - Obalon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 55.49M
Enterprise Value 3-1.77M
Trailing P/E N/A
Forward P/E 1-1.65
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)2.40
Price/Book (mrq)0.50
Enterprise Value/Revenue 3-0.77
Enterprise Value/EBITDA 60.10

Trading Information

Stock Price History

Beta (5Y Monthly) -1.12
52-Week Change 3-87.82%
S&P500 52-Week Change 35.18%
52 Week High 310.5000
52 Week Low 30.6200
50-Day Moving Average 30.9073
200-Day Moving Average 31.2223

Share Statistics

Avg Vol (3 month) 3706.21k
Avg Vol (10 day) 3273.52k
Shares Outstanding 57.73M
Float 6.61M
% Held by Insiders 14.12%
% Held by Institutions 128.05%
Shares Short (Jun. 14, 2020) 4494.43k
Short Ratio (Jun. 14, 2020) 40.49
Short % of Float (Jun. 14, 2020) 47.46%
Short % of Shares Outstanding (Jun. 14, 2020) 46.39%
Shares Short (prior month May 14, 2020) 4397.81k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Jul. 24, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-828.61%

Management Effectiveness

Return on Assets (ttm)-45.89%
Return on Equity (ttm)-234.76%

Income Statement

Revenue (ttm)2.29M
Revenue Per Share (ttm)0.38
Quarterly Revenue Growth (yoy)-56.10%
Gross Profit (ttm)384k
EBITDA -18.51M
Net Income Avi to Common (ttm)-20.65M
Diluted EPS (ttm)-3.4070
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.91M
Total Cash Per Share (mrq)1.15
Total Debt (mrq)1.66M
Total Debt/Equity (mrq)14.98
Current Ratio (mrq)2.17
Book Value Per Share (mrq)1.43

Cash Flow Statement

Operating Cash Flow (ttm)-18.04M
Levered Free Cash Flow (ttm)-8.73M